BLS Pharmaceuticals Limited
0.93
AUD
0.00
(0.00%)
ISIN
AU0000477796
Return %
Stock
S&P 500
1Y
143.42
14.20
3Y
740.91
81.12
5Y
242.59
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Sam Watson
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Level 5 Sydney NSW Australia 2000
- IPO Date
- Dec 12, 2000
- Website
- bioxyne.com
- Similar Companies
- Business
- BLS Pharmaceuticals Limited, a specialty pharmaceutical company, engages in the research, development, manufacture, and distribution of prescription medicines and nutritional products for global markets. The company focuses on cardiovascular, metabolic, oncology, and central nervous system therapeutic areas, delivering branded and generic pharmaceutical products across multiple geographies. Headquarters are in Sydney, Australia, with operations spanning Australia, New Zealand, Southeast Asia, and select global export markets. BLS Pharmaceuticals Limited is publicly listed on the Australian Securities Exchange under ticker BLS.AX and traces its roots to established manufacturing facilities and R&D centers acquired or integrated over the past two decades. Main products and services: core pharmaceutical products including branded prescription medicines across cardiovascular, oncology, metabolic, and CNS segments; generic formulations addressing high-priority therapeutic areas; over-the-counter and consumer health products; contract manufacturing and licensing services for third-party pharmaceutical developers; clinical trial supply and packaging services; regulatory affairs and quality assurance support; research and development programs focusing on novel delivery platforms and formulation optimization; manufacturing of small- and medium-volume batches for regional markets; supply chain management and distribution services; packaging, labeling, and serialization to meet regional regulatory requirements; associated nutraceuticals and dietary supplements marketed through select channels; ongoing clinical development partnerships and co-development initiatives with industry collaborators. Latest major company changes: forms strategic partnerships with regional distributors to expand market access in Asia-Pacific; completes a major funding round to accelerate development of specialty generics and complex formulations; acquires a complementary mid-cap specialty pharma business to widen therapeutic reach and manufacturing capabilities; launches a next-generation drug delivery platform for oral and injectable therapies; reaffirms expansion plans with new production lines and capacity upgrades at existing facilities; undergoes corporate rebranding and organizational realignment to enhance global market focus and streamline governance; reports significant operational changes including installation of updated GMP-compliant manufacturing suites and increased regulatory filing activity across multiple jurisdictions within the last 1–2 years. Additional context: industry and segments include pharmaceutical manufacturing, generic and branded medicines, contract development and manufacturing organization (CDMO) services, specialty therapeutics, nutraceuticals, and distribution. Target markets comprise hospitals, clinics, wholesalers, and specialty pharmacies in developed and emerging markets. Geographic footprint covers Australia, New Zealand, Southeast Asia, and export operations in North America and Europe through distribution and licensing arrangements. Subsidiaries and parent relationships include regional manufacturing affiliates and a holding structure coordinating global product registrations and supply chain governance. The company emphasizes R&D collaboration with academic and industry partners to advance formulation science and delivery technologies.